COVID-19 Prevention Study
This is a Clinical Research Study to evaluate the efficacy, safety, and tolerability of a study medication for the prevention of infection in people ("study participant") who live in the same household with a person/family member who is infected with COVID-19
The purpose of the study is to assess if the study medication will prevent symptomatic coronavirus disease (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, double-blind, placebo-controlled study; half of the study participants will receive actual study medication twice daily orally and the other half will receive a placebo. The primary objectives of the study are to determine if the study medication prevents the spreading of symptomatic COVID-19 disease. All participants who develop COVID-19 during the study are still eligible for any COVID-19 treatment recommended by their doctor.
Criteria:
Must be 18 Years and older;
Lives in a household with a person with documented COVID-19 infection with symptoms and must have
1) Has a detectable SARS-CoV-2 test result from a sample collected/confirmed by a doctor, medical institution/lab within 3 days prior to randomization of the participant,
2) Must have at least 1 symptom attributable to COVID-19 (e.g., fever, difficulty breathing, etc.)
3) Willing and able to take oral medication